Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response

Published:2020-12-31 Issue:1 Volume:13 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Dela Cruz Chuh Josefa¹,Go MaryAnn²,Chen Yvonne³,Guo Jun²,Rafidi Hanine⁴,Mandikian Danielle⁴,Sun Yonglian³,Lin Zhonghua³,Schneider Kellen³,Zhang Pamela³,Vij Rajesh³,Sharpnack Danielle¹,Chan Pamela¹,de la Cruz Cecile²,Sadowsky Jack⁵,Seshasayee Dhaya³,Koerber James T.³,Pillow Thomas H.⁶^ORCID,Phillips Gail D.²,Rowntree Rebecca K²,Boswell C. Andrew⁴,Kozak Katherine R.¹,Polson Andrew G.²,Polakis Paul²,Yu Shang-Fan²,Dragovich Peter S.⁶,Agard Nicholas J.³

Affiliation:

1. Departments of Biochemical and Cellular Pharmacology, Genentech Inc, South San Francisco, CA, USA

2. Research biology, Genentech Inc, South San Francisco, CA, USA

3. Antibody Engineering, Genentech Inc, South San Francisco, CA, USA

4. Preclinical & Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, South San Francisco, CA, USA

5. Protein Chemistry, Genentech Inc, South San Francisco, CA, USA

6. Discovery Chemistry, Genentech Inc, South San Francisco, CA, USA

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2020.1862452

Reference57 articles.

1. An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies

2. Deletion of the Syncytin A receptor Ly6e impairs syncytiotrophoblast fusion and placental morphogenesis causing embryonic lethality in mice

3. Emerging Role of LY6E in Virus–Host Interactions

4. Overexpression of Lymphocyte Antigen 6 Complex, Locus E in Gastric Cancer Promotes Cancer Cell Growth and Metastasis

5. Yeom CJ, Zeng L, Goto Y, Harada H. LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis. Oncotarget. 2016:1–12. doi:https://doi.org/10.18632/oncotarget.11670

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to Therapy;Journal of the American Chemical Society;2024-07-01

2. A novel, label‐free, pre‐equilibrium assay to determine the association and dissociation rate constants of therapeutic antibodies on living cells;British Journal of Pharmacology;2023-11-05

3. Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases;Journal of Pharmaceutical Sciences;2023-11

4. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment;Anti-Cancer Agents in Medicinal Chemistry;2023-04

5. Genomic and Transcriptomic Analyses of NF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment;Journal of Investigative Dermatology;2023-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3